BioSpace News Archive

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX ® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent

Assembly Biosciences, Inc. today outlined anticipated progress and milestones for its development pipeline in 2022.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.

Solid Biosciences Inc. today announced the grant of inducement awards to its newly appointed Senior Vice President, Human Resources, Allison Bogosian.

Vor Biopharma, a clinical-stage cell and genome engineering company, announced that members of its senior management team will be participating in two upcoming virtual investor conferences.

Longeveron Inc. announced that Geoff Green, Chief Executive Officer of Longeveron, will present at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participate in a panel discussion moderated by Dr. Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration.

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.

Cocrystal Pharma, Inc. announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today reported positive interim safety data in the Phase Ib “safety run-in” segment of the KEYNOTE B84 combination study of Keytruda®.

Perrigo Company plc (NYSE; TASE: PRGO), announced today that President and CEO, Murray S. Kessler is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM (EST) .